S2 Ep7: Kami Maddocks, MD, on Rituximab Rechallenging and Second-Line Therapies for R/R DLBCL

Update: 2021-07-30

Description

CancerNetwork spoke with Kami Maddocks MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University, about CD-19 directed agents, avoiding rechallenging with rituximab, and second-line outcomes for transplant-ineligible patients with diffuse large B-cell lymphoma (DLBCL).

Visit cancernetwork.com to check out the first episode of this 3-part series here.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

$S2 Ep26: Between the Lines Podcast: Tazemetostat in Relapsed/Refractory Follicular Lymphoma$

S2 Ep26: Between the Lines Podcast: Tazemetostat in Relapsed/Refractory Follicular Lymphoma

2022-11-0321:10

$S2 Ep25: Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma$

S2 Ep25: Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

2022-05-2022:24

S2 Ep24: OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

2022-05-0634:36

S2 Ep23: OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC

2022-04-2930:07

S2 Ep22: Between the Lines™ Podcast: Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC

2022-04-2727:37

S2 Ep21: OncView™ Podcast: EGFR Exon 20 Insertion as Therapeutic Target in NSCLC

2022-04-0821:01

S2 Ep20: Between the Lines™ Podcast: ctDNA as a Biomarker of Progression in Colorectal Cancer

2022-04-0525:24

S2 Ep19: OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

2022-04-0243:51

S2 Ep18: OncView™ Podcast: Immunotherapy Response Monitoring in Lung Cancer

2022-03-3018:12

S2 Ep17: Between the Lines™ Podcast: Incorporating Real-World Evidence into Clinical Decisions in NSCLC

2022-01-1441:45

S2 Ep16: Future Directions in Small Cell Lung Cancer Treatment

2021-12-2207:44

S2 Ep15: Practical Considerations for Small Cell Lung Cancer Therapeutic Options

2021-12-1613:21

$S2 Ep14: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer$

S2 Ep14: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer

2021-12-0213:38

S2 Ep13: First-Line Therapeutic Options in Small Cell Lung Cancer

2021-11-0110:08

S2 Ep12: OncView™ Podcast: Connie Batlevi, MD, PhD on R/R Follicular Lymphoma Therapy Updates

2021-10-2925:10

S2 Ep11: Between the Lines: PET/CT-Guided Postprostatectomy Salvage Radiotherapy for Prostate Cancer

2021-10-1936:20

S2 Ep10: Two Experts Review Important R/R DLBCL Treatment Decisions and Data

2021-08-3018:13

$S2 Ep9: OncView™ Podcast: Updates in Therapies of Relapsed/Refractory Follicular Lymphoma$

S2 Ep9: OncView™ Podcast: Updates in Therapies of Relapsed/Refractory Follicular Lymphoma

2021-08-2520:09

S2 Ep8: OncView™ Podcast: NCCN Guideline Updates in HR+ Breast Cancer

2021-08-2023:22

S2 Ep7: Kami Maddocks, MD, on Rituximab Rechallenging and Second-Line Therapies for R/R DLBCL

2021-07-3014:25

00:00

S2 Ep7: Kami Maddocks, MD, on Rituximab Rechallenging and Second-Line Therapies for R/R DLBCL

#box-pro-ellipsis-173697515997166{-webkit-line-clamp:2;}S2 Ep7: Kami Maddocks, MD, on Rituximab Rechallenging and Second-Line Therapies for R/R DLBCL

S2 Ep7: Kami Maddocks, MD, on Rituximab Rechallenging and Second-Line Therapies for R/R DLBCL

CancerNetwork

S2 Ep7: Kami Maddocks, MD, on Rituximab Rechallenging and Second-Line Therapies for R/R DLBCL